Edition:
United States

BB Biotech AG (BION.S)

BION.S on Swiss Exchange

52.80CHF
23 Jan 2017
Change (% chg)

-- (--)
Prev Close
CHF52.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
127,321
52-wk High
CHF58.00
52-wk Low
CHF38.98

BION.S

Chart for BION.S

About

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s... (more)

Overall

Beta: 1.18
Market Cap(Mil.): CHF2,988.83
Shares Outstanding(Mil.): 55.40
Dividend: 2.75
Yield (%): 5.38

Financials

  BION.S Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -4.95 -- --
ROI: -8.23 -1.38 14.86
ROE: -8.23 -1.07 16.28

BRIEF-BB Biotech proposes dividend of CHF 2.75 per share

* Portfolio performs well in in the volatile fourth quarter of 2016

Jan 20 2017

BRIEF-BB Biotech FY 2016 result swings to loss of CHF 802 million

* Closed business year 2016 based on preliminary unaudited consolidated results with a loss of approximately 802 million Swiss francs (-$794.77 million) (653 million Swiss francs profit in previous year) Source text for Eikon: Further company coverage: ($1 = 1.0091 Swiss francs) (Gdynia Newsroom)

Jan 13 2017

BRIEF-BB Biotech Q3 profit of CHF 392.1 million

* Resulting profit for Q3 2016 is 392.1 million Swiss francs ($394.07 million) Source text for Eikon: Further company coverage: ($1 = 0.9950 Swiss francs) (Gdynia Newsroom)

Oct 21 2016

BRIEF-BB Biotech swings to prelim Q3 profit of CHF 392.1 mln

* Based on preliminary unaudited consolidated results, BB Biotech closed Q3 of 2016 with a profit of 392.1 million Swiss francs ($401.41 million)(575.4 million francs loss in corresponding period of previous year)

Oct 11 2016

BRIEF-BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics

* BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing Source text for Eikon: Further company coverage:

Sep 27 2016

Earnings vs. Estimates